top of page

Antidiarrheal with novel MOA
Not an antibiotic
Plant-based and well tolerated

Bottle_Leaves_0722-49.png

Canalevia-CA1 is the only antidiarrheal conditionally approved to treat chemotherapy-induced diarrhea (CID) in dogs.

LEADING TO RELIEF

Circle_Graphic.png

INDICATION: CANALEVIA-CA1 is indicated for the treatment of chemotherapy-induced diarrhea in dogs.

​

ADVERSE REACTIONS: The most common side effects are decreased appetite and activity, dehydration, stomach pain and vomiting.

BVD-005-1122

Contact Us

 

1 (877) 787-3001

info@canalevia.com

  • Instagram
  • Facebook
  • LinkedIn

Location

 

Jaguar Animal Health

200 Pine Street, Suite 600

San Francisco, CA 94104

Home

Contact Us

Resources

Events

About Us

Join Our Mailing List

Investor Relations

Partnering with Canalevia-CA1

Canalevia_byJAG_Logo_White.png

Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.

CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. It is a violation of Federal Law to use this product other than as directed in the labeling.

​

IMPORTANT SAFETY INFORMATION

For oral use in dogs only. Not for use in humans. Keep Canalevia®-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.

bottom of page